Browse the evidence

Semaglutide improves the function and inflammatory status of endothelial progenitor cells (EPCs) by inhibiting LPS-induced macrophage expression of miR-155 in exosomes.

Semaglutide may be beneficial in improving endothelial function in obesity-related inflammation.

LPS-induced macrophage exosomes reduce the cellular activity, migratory capacity, and tube-forming ability of EPCs.

Inflammation from macrophage exosomes can impair endothelial repair mechanisms.

Semaglutide alleviated metabolic disorders, ameliorated myocardial fibrosis, improved cardiac function, antagonized oxidative stress, and suppressed cardiomyocyte apoptosis in diabetic mice.

Semaglutide may be beneficial for improving heart health in diabetic patients.

Gastrointestinal adverse events occur commonly with semaglutide, and other serious adverse events have been reported.

Healthcare providers should monitor patients for gastrointestinal and other serious adverse events while on semaglutide.

There are existing knowledge gaps in the molecular and cellular processes underlying exercise-induced benefits and adaptations.

Researchers should focus on addressing these gaps to advance the understanding of exercise physiology.

Fructose resets ATP levels to a lower level in the cell, suppressing mitochondrial function.

Understanding fructose's impact on ATP may inform dietary recommendations.

The development of new drug combinations may provide alternative treatment options for OSA.

Practitioners should explore new drug combinations as potential treatments for OSA.

Tirzepatide treatment significantly decreased Alt-Ext-induced IL-5 and IL-13 levels in lung homogenates compared with vehicle treatment.

Tirzepatide may help reduce allergic inflammation in obese asthma patients.

The incidence of gastrointestinal adverse effects with tirzepatide was similar to that of semaglutide.

Tirzepatide may have a similar safety profile regarding gastrointestinal effects compared to semaglutide.

The most common adverse events associated with semaglutide are gastrointestinal in nature.

Healthcare providers should inform patients about potential gastrointestinal side effects when prescribing semaglutide.

Ex-DARPin fusion proteins significantly improved the survival of pancreatic islets in diabetic mice.

Improving pancreatic islet survival could enhance insulin production and overall diabetes management.

There is a complex and bidirectional relationship between adipose and breast tissues.

Understanding this relationship can help in developing targeted interventions for breast cancer.

Recent innovations in obesity diagnosis include bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA) scans, alongside emerging biomarkers from 'omics' technologies.

Healthcare practitioners should consider incorporating BIA and DXA scans for more accurate obesity diagnosis.

The pathogenesis of obesity-related glomerulopathy is complex, involving multiple factors.

Recognizing the complexity of ORG can guide more targeted therapeutic approaches.

The internet-based marketing of plant-based formulations for enhancing metabolism has surged.

Practitioners should be aware of the growing trend in plant-based metabolism enhancers in the market.

GIP(1-30)NH2 and GIP(1-42) have similar effects on human pancreatic islets.

Both GIP variants can be expected to have similar effects on insulin and glucagon secretion in pancreatic islets.

The SDOC definition has high discriminatory accuracy for identifying ADL disability.

The SDOC criteria can be effectively used to assess risk of ADL disability in older adults.

Research is ongoing to develop improved GLP-1-based therapies, including oral small-molecule agonists and novel drug delivery strategies.

Practitioners should stay informed about emerging GLP-1 therapies that may improve patient compliance.

18F-FDG PET scanning is the most commonly used imaging modality to detect and quantify human BAT activity in vivo.

Clinicians can utilize 18F-FDG PET for assessing BAT activity in patients.

Tissue concentrations and mRNA expression of GLP-1 and PYY do not differ between individuals with obesity and lean controls.

This indicates that obesity does not alter the local production of GLP-1 and PYY in the gut.

GLP-1 RA therapy was associated with a low rate of major adverse events in LVAD patients.

GLP-1 RA appears to be a safe adjunct therapy for LVAD patients.

GLP-1 RA therapy was not associated with increased incidence of GI cancers.

GLP-1 RAs may be a safer option regarding GI cancer risk for patients with type 2 diabetes.

No significant differences were observed in biliary cancer or hepatocellular carcinoma between GLP-1 RAs and other oral antidiabetic medications.

Clinicians can consider GLP-1 RAs without increased concern for biliary or liver cancer risks.

Both drugs are associated with kidney and thyroid disorders.

Healthcare providers should monitor kidney and thyroid function in patients using these medications.